Viagra for safer births? withdrawn trial leaves questions unanswered

NCT ID NCT06377098

Terminated Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study planned to give sildenafil (the drug in Viagra) to women in labor in low-resource areas, aiming to reduce fetal distress and birth asphyxia. It was designed to test whether the drug could be safely given and to gather data for a larger trial. However, the study was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sildenafil (the active ingredient in Viagra, given as 50 mg oral tablets during labor)
What this could lead to: If it had worked, this could have pointed toward a simple, low-cost way to reduce birth complications like oxygen deprivation in newborns.
What could go wrong: The trial was withdrawn before enrolling anyone, so no data exist. Even if conducted, it was a small pilot study, so results would be preliminary and might not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEVELOPMENT, INFANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

perinatal asphyxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEVELOPMENT, INFANT INTRAPARTUM ASPHYXIA INTRAPARTUM FETAL DISTRESS NEONATAL ASPHYXIA

Viagra for safer births? withdrawn trial leaves questions unanswered

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions